Human T helper 17 (T H 17) cells regulate host defense, autoimmunity, and tumor immunity. Although cytokines that control human T H 17 cell development have been identified, the costimulatory molecules important for T H 17 cell generation are unknown. Here, we found that the inducible costimulator (ICOS) was critical for the differentiation and expansion of human T H 17 cells. Human cord blood contained a subset of CD161 + CD4
I M M U N O L O G Y

The Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells
Chrystal M. Paulos, 1 
INTRODUCTION
CD4
+ T cells are important in regulating immunity to pathogens, allergic responses, asthma, and immunity to self or tumor tissues (1) (2) (3) . Depending on the microenvironmental cues present, naïve CD4 + T cells may differentiate into one of several T helper (T H ) cell lineages, including T H 1, T H 2, T H 17, T H 22, and regulatory T (T reg ) cells (4, 5) . T H 1 and T H 2 cells are effector cells that express T-bet and GATA-3, respectively (1) . In contrast, T reg cells suppress effector T cell functions and are essential for regulating autoimmune responses (6) , and the recently described T H 22 cells secrete interleukin-22 (IL-22) and might be a subset of skin-homing cells responsible for inflammation (7, 8) . T H 17 cells augment host defense, have a major role in mucosal immunity, enhance a number of autoimmune diseases, and release cytokines, including IL-17A and IL-17F (9). The contribution of T H 17 cells to tumor immunity varies, showing the potential for both antitumorigenic and protumorigenic activity (10) . Therefore, identification of the mechanisms that control T H 17 responses is essential to understand tumor immunity.
The functions of cytokines [for example, transforming growth factor-b (TGF-b), IL-6, IL-1b, IL-21, and IL-23] and transcription factors (such as RORC2 and RORa) in human T H 17 cell development are distinct from T H 1 and T H 2 effector cells (11) (12) (13) (14) . Further, natural agonists for the aryl hydrocarbon receptor (AHR) augment murine T H 17 cell differentiation (15) . However, the specific costimulatory pathways that may influence T H 17 generation and stability remain to be elucidated.
Antigen-specific and antigen-nonspecific costimulatory signals from antigen-presenting cells (APCs) are necessary for the activation, differentiation, and function of T lymphocytes (16) . CD28 is considered to be the primary co-signaling molecule on CD4 + T cells because of its early expression, and it is often used to generate IL-17-producing lymphocytes (12) (13) (14) (17) (18) (19) . However, in addition to CD28, signaling via the inducible costimulator (ICOS, also called CD278) is required for optimal cytokine secretion, because both molecules are essential for optimal IL-17A secretion by murine T H 17 cells (20) . Recent findings in murine models have revealed that ICOS amplifies T H 17 responses by inducing the expression of the transcription factor c-MAF and therefore transactivating IL-21 production (21). Although both CD28 and ICOS are important for the generation of murine T H 17 cells, their particular roles in regulating key genes in human T H 17 cells remain to be identified.
Here, we show that the nature of costimulation during CD4 + T cell activation critically regulates human T H 17 cell differentiation. ICOS, but not CD28, is necessary for optimal expansion and function of human T H 17 cells. Surprisingly, CD28 ligation abrogated the effects of ICOS costimulation. These data are surprising given that CD28 is often used to expand human T H 17 cells, and they raise the possibility that the full inflammatory potential of human T H 17 cell in vivo has not been fully reflected by previous in vitro studies. Of clinical relevance, genetically reprogrammed human T H 17 cells expanded with ICOS mediated superior regression of human tumors compared to cells expanded with CD28. These findings reveal a key role for ICOS signaling in human T H 17 cell development and suggest new therapeutic approaches.
RESULTS
ICOS and CD28 have distinct effects on human CD4
+ T cell subsets ICOS was originally identified as a molecule expressed on T cells only after activation (22) . Constitutive expression of ICOS was later found on a subpopulation of resting murine effector memory T cells, T reg cells, and follicular helper T (TFH) cells (23) (24) (25) . Given the recent identification of human T H 17 cells, we sought to examine whether ICOS was also constitutively expressed on these cells. We sorted resting peripheral blood CD4 + T cells into various subsets based on their expression of chemokine receptors and other cell surface molecules. This strategy yielded T H 1 ( (18, 26, 27) . Surprisingly,~40% of cells in the T H 17 subset constitutively expressed ICOS, whereas the T H 1 and T H 2 subsets did not express ICOS (Fig. 1, A and B). As expected, T reg and TFH subsets constitutively expressed ICOS (23) (24) (25) , whereas all subsets constitutively expressed CD28 at high levels ( Fig. 1, A and B).
Given that human T cell subsets constitutively express varying amounts of ICOS and CD28, we sought to evaluate the functional effects of signaling via these particular molecules on each subset. Thus, subsets were sorted as described above and then stimulated with antibodies to CD3/CD28 or CD3/ICOS beads. IL-2, IL-4, interferon-g (IFN-g), IL-10, IL-22, IL-17A, IL-17F, CCL20, and IL-21 production was measured by enzyme-linked immunosorbent assay (ELISA) (Fig. 1C) . As expected, all subsets except T reg cells secreted substantial amounts of IL-2 after CD28 costimulation (Fig. 1C, i ). In contrast, ICOS costimulation did not trigger IL-2 secretion, corroborating our previous finding that CD28, but not ICOS, mediates IL-2 production by T cells (28, 29) . Furthermore, CD28, but not ICOS, induced IL-4 production by T H 2 cells (Fig.  1C, ii) . IL-10 and IL-22 secretion was triggered by both CD28 and ICOS costimulation in a subset-specific manner, although in most subsets CD28 costimulation induced higher amounts of these cytokines (Fig. 1C,  iv and v) . In contrast, ICOS costimulation of T H 17 cells resulted in significantly higher production of IL-17A, IL-17F, CCL20, and IL-21 compared with CD28 costimulation (Fig.  1C, vi to ix) . Notably, ICOS-stimulated T H 17 cells also produced greater amounts of IFN-g than CD28-stimulated T H 1 cells, a subset reported to be a dominant source of IFN-g secretion (Fig. 1C, iii Fig. 2A) , supporting the notion that ICOS might play a unique role in human T H 17 cell development.
We next asked whether ICOS engagement alone might be sufficient to induce IL-17F secretion by bulk unpolarized CD4 + T cells. We found that ICOS engagement was not sufficient to promote significant IL-17F production in the absence of T H 17-polarizing conditions. However, in the presence of T H 17-polarizing conditions, ICOS induced IL-17F secretion from bulk CD4 + T cells (Fig. 2B) . Delivery of the ICOS signal via either beads or aAPCs was equally effective at inducing IL-17F secretion (Fig.  2B) (20) . Therefore, we suspected that they would also augment human T H 17 function in combination. Conversely, the addition of CD28 with ICOS markedly reduced IL-17F secretion (Fig. 2C ) and IL-17A messenger RNA (mRNA) expression (Fig. 2D ). Yet, combining these signals did not exert a similar "veto effect" on IL-2, IL-10, or IL-22 secretion (Fig. 2, E 
CD4
+ T cells was~16% (Fig. 3A) . However, a progressive decrease in the frequency of these cells was observed in the CD28-costimulated culture. In contrast, the frequency of CCR4 + CCR6 + CD4 + T cells was stable, and even increased slightly, in the ICOS- costimulated culture. The selective outgrowth of these cells by ICOS was apparent when their absolute numbers were compared to those expanded with CD28 (Fig. 3B) + T cells produced IL-17A after the first 5 to 7 days of expansion (Fig. 3D) , consistent with previous reports. However, the frequency of CD28-engaged T H 17-polarized cells producing IL-17A or both IL-17A and IFN-g declined nearly to baseline levels by the end of their primary expansion. In contrast, the frequency of these cells increased over time in ICOS-costimulated cultures ( Fig. 3D ), a finding reproduced in several independent cultures. Cells engaged with ICOS coexpressed both transcription factors RORC2 and T-bet ( 
ICOS and CD28 have distinct roles in development of T H 17 cells derived from cord blood
The above data indicated that ICOS preferentially expands effector human T H 17 cells, but these data did not discern whether ICOS supports their development from naïve CD4 + T cells. Bauquet and coworkers reported that ICOS was crucial for the expansion but not the development of murine T H 17 cells (21 
CD4
+ T cells from umbilical cord blood (UCB), cultured them in T H 17-polarizing conditions, and activated them with an antibody to CD3 beads bearing antibodies to CD28 and/or ICOS. The function and phenotype of the cultures were assessed after primary (day 11) and secondary (day 18) stimulation ( Fig. 4 scheme) . IL-17A, IFN-g, IL-2, and tumor necrosis factor-a (TNF-a) were measured after phorbol 12-myristate 13-acetate (PMA)-ionomycin activation. We found that >40% of cells engaged with ICOS   CD28  ICOS  CD28  ICOS  CD28  ICOS  CD28  ICOS  CD28  ICOS   CD28 ICOS produced IL-17A alone or IFN-g alone and that~20% of ICOSengaged cells secreted both cytokines. In contrast, few cells engaged with CD28 produced IL-17A (Fig. 4, A and B) . CD28 was indeed functional under these conditions because~10% of these cells produced IFN-g and >50% of these cells produced IL-2 after CD28 or CD28 plus ICOS costimulation (Fig. 4, A and C ). Yet, only~10% of cells secreted IL-2 after ICOS costimulation alone (Fig. 4B ). Combining CD28 with ICOS costimulation prevented IL-17A production, and IFN-g was produced by these cells at similar levels to CD28 stimulation alone (Fig. 4C) . Primary engagement of cells with ICOS but not CD28 induced substantial TNF-a and IL-17A coexpression. CD161 expression was assessed as well, because human T H 17 cells originate from CD161 + CD4 + T cell precursors in UCB (32) . Nearly half of cells engaged with ICOS coexpressed CD161 and IL-23 receptor (IL-23R) (Fig. 4B) , whereas <5% of cells engaged with CD28 or CD28 plus ICOS were IL-23R-and CD161-positive (Fig. 4, A S1 ). Examination of cells after secondary expansion revealed that cells originally stimulated with ICOS continued to secrete high amounts of IL-17A, IFN-g, and TNF-a, and this was independent of the mode of secondary costimulation (Fig. 4E) . Likewise,~30% of these cells continued to coexpress IL-23R and CD161. However, virtually no UCB T H 17-polarized cells initially stimulated with CD28 or with CD28 plus ICOS secreted IL-17A, even after a restimulation with ICOS (Fig. 4, D and F) . Thus, CD28 costimulation does not block IL-17A secretion after primary induction by unopposed ICOS costimulation (Fig. 4, B and E) . These data suggest an important role for ICOS in programming T H 17 development from naïve human UCB CD4 + T cells.
ICOS augments human T H 17 function by inducing c-MAF and IL-21
We next investigated the mechanisms underlying enhanced human T H 17 cell functionality via ICOS. In mice, ICOS induces the transcription factor c-MAF, which, in turn, transactivates IL-21 and augments T H 17 function (21). We investigated whether ICOS also induces c-MAF in human T H 17 cells, given that ICOS increases IL-21 secretion (Fig. 1C, ix) . Human UCB CD4 + T cells polarized toward a T H 17 phenotype expressed considerably higher mRNA concentrations of c-MAF and IL-21 upon ICOS versus CD28 costimulation (Fig. 5, A and B) . Similar results were observed in peripheral blood human T H 17 cells (fig. S2 ). Thus, ICOS induced greater amounts of c-MAF expression than CD28, corresponding with increased IL-21 expression by ICOS-stimulated human T H 17 cells.
We hypothesized that IL-21 induced by ICOS was partially responsible for enhanced human T H 17 cell functionality. Thus, we assessed whether adding exogenous IL-21 to CD28-stimulated T H 17-polarized UCB CD4 + T cells would increase their potential to secrete IL-17F. Consistent with previous studies (13), adding IL-21 to CD28-stimulated T H 17-polarized UCB cells modestly increased their capacity to secrete IL-17F but not to the level attained by ICOS-stimulated T H 17-polarized UCB cells (Fig. 5C) . Given that T H 17 cells costimulated with CD28 secrete significantly higher amounts of IL-2 than those stimulated with ICOS, we hypothesized that IL-2 might be responsible for the reduced functionality observed in CD28-stimulated T H 17-polarized UCB cells. Indeed, IL-17F production was increased in the cultures where IL-2 was neutralized. Furthermore, exogenous IL-21 together with IL-2 neutralization in the culture of CD28-stimulated T H 17-polarized UCB cells further increased IL-17F production, but it still did not induce IL-17F secretion to a level comparable to that elicited by ICOS stimulation (Fig.   5C ). Thus, in addition to c-MAF-mediated IL-21 production, other factors are likely involved in mediating the ICOS-enhanced function of human T H 17-polarized UCB cells.
ICOS induces RORC2 expression
To better understand the mechanisms underlying how ICOS signaling augmented the functionality of human T H 17 cells, we investigated how ICOS regulates the cell expression of RORC2 (RORgt), T-bet (Tbx21), and FoxP3, master regulators of T H 17, T H 1, and T reg cells (1), respectively. Thus, RORC2, T-bet, and FoxP3 were measured in naïve UCB CD25 −
CD4
+ T cells cultured in T H 17-polarizing conditions over time via flow cytometry. At baseline, the cells expressed virtually no RORC2, T-bet, or FoxP3; there was a transient activation-associated increase in their expression in each culture at 3 to 5 days after stimulation (Fig. 5, D and E) . However, by the end of their primary expansion, we found that >75% of ICOS-stimulated cells expressed RORC2 (Fig. 5, D and E, days 7 to 10). In contrast, the frequency of CD28-expanded cells expressing RORC2, T-bet, and FoxP3 progressively declined (Fig. 5, D and E). Likewise, ICOS induced greater mRNA expression of RORC2 and T-bet than CD28 (Fig. 5, F and G) , whereas CD28 induced greater yet transient mRNA expression of FoxP3 than ICOS in these cells (Fig. 5H) . Similar to peripheral blood data ( Fig. 2F and fig. S3 ), CD28 induced higher expression of the AHR transcripts than ICOS (Fig. 5I) , likely resulting in their heightened production of IL-22 (Fig. 5J) . These data are consistent with findings in mice showing that AHR correlates with IL-22 production by T cells (15, 33) . IL-10 expression was comparable in cells stimulated with either CD28 or ICOS (Fig. 5K) , whereas IL-17A expression was significantly higher in cells stimulated with ICOS versus CD28 over time (Fig. 5L) . RORC2 transcripts were stably induced at high amounts throughout the culture compared to T-bet and FoxP3 transcripts in cells stimulated with ICOS (Fig. 5, F to H) .
We suspected that the amounts of IL-17A with CD28 costimulation might be low because the cells were differentiated in serum without the addition of TGF-b. Indeed, titrating TGF-b into the culture over a 3-log 10 range of concentration increased the amount of IL-17A produced by T H 17-polarized CD4 + T cells expanded with the CD28 signal but not to the amounts reached by ICOS-stimulated cells ( fig. S4 ). These data underscore the notion that CD28-costimulated T cells are composed of T H 17 cells that have not reached their full inflammatory potential. Further, they reveal the importance of the availability of TGF-b in the microenvironment as well as CD28 "veto signaling" (Fig. 2, C and D 
+ T H 17 cells (Fig. 1, A and B) ,~50% of resting CD161 + CD4
+ cord blood T cells expressed ICOS (Fig. 6A) (Fig. 6A) , as indicated by comparable high expression of CD45RA, CD127, CD62L, and CD27, and bright expression of CD31, which is typical of recent thymic emigrants (34). (Fig. 6B) (Fig. 6C) .
R E S E A R C H A R T I C L E
It has been reported that CD161 + CD4 + T cells constitutively express RORC2 and IL-23R and that T H 17-polarizing conditions further upregulate expression of these molecules (32) . Given our findings, we hypothesized that CD161 (Fig. 6D) , corresponding with their increased IL-17F and CCL20 secretion (Fig. 6B) . In contrast, CD28 engagement induced higher mRNA expression amounts of AHR in ICOS + CD161 + CD4 + T cells (Fig. 6D ), consistent with their enhanced IL-22 production (Fig. 6B) . Thus, in addition to CD161, ICOS might be a surface marker for UCB CD4 + T cells that develop into T H 17 cells.
Given + T cells induced IL-17A secretion even under T H 1-, T H 2-, or T reg -polarizing conditions, although at varying amounts (Fig. 6E) . In contrast, costimulation through CD28 induced modest amounts of IL-17A secretion, even in the presence of T H 17-polarizing conditions (Fig. 6E) . Conditions that polarize bulk UCB CD4 + T cells toward a T H 1, T H 2, T H 17, and T reg cell phenotype were effective because they promoted IFN-g, IL-4, IL-17A secretion, or FoxP3 expression, respectively ( fig. S6 ). In contrast, ICOS costimulation of ICOS + CD161 + CD4
+ T cells was unable to elicit IL-4 secretion and failed to promote FoxP3 expression when cultured in conditions that fostered their T H 2 or T reg development ( fig. S6) . Regardless of the T cell subset-polarizing conditions and the mode of costimulation, we found that less than 5% of ICOS
+ T cells produced IL-17A (Fig. 6E) 
ICOS augments T cell-mediated tumor immunity
We have reported that genetically redirected peripheral blood T cells expanded with antibodies to CD3/CD28 beads mediate robust antitumor effects after infusion into mice bearing human tumor xenografts (35) . Given our finding that ICOS costimulation in the presence of T H 17-polarizing conditions generates IL-17A + IFN-g + T lymphocytes in vitro, we wished to investigate how these cells, upon genetic redirection, would affect the growth of human tumors. To test this question, we expanded bulk peripheral blood T cells with antibodies to CD3/CD28 or CD3/ICOS beads in the presence or absence of T H 17-polarizing conditions and genetically modified them with a chimeric antigen receptor (CAR) to confer specificity for mesothelin-expressing tumors (Fig. 7  scheme) . NOD/scid/IL-2Rg null mice were injected in the flank with the human mesothelioma cell line M108 and were injected intratumorally with the redirected cells beginning on day 61 after tumor challenge. We found that mice treated with ICOS-stimulated T cells polarized with T H 17 cytokines experienced superior tumor regression compared with all other treatment groups (P < 0.005; Fig. 7 , D versus A to C). Only cells stimulated with ICOS in the presence of T H 17-polarizing conditions were able to mediate regression of large tumors (Fig. 7D) . Cells stimulated by CD28 alone or by CD28 plus T H 17-polarizing conditions were able to slow tumor progression, but were unable to mediate long-lasting tumor regression (Fig. 7, A to C) . The therapeutic effectiveness of polarized cells stimulated with ICOS may be a consequence of their enhanced IFN-g secretion upon antigen recognition ex vivo (Fig. 7E) and increased engraftment in vivo (Fig. 7F) . Our findings identify ICOS and its downstream signaling pathways as a target for the development of cancer immunotherapy to modify T H 17 cell function and numbers.
DISCUSSION
Phylogenetic studies indicate that the co-signaling molecule ICOS arose as a duplication of CD28 and that this event was coincident with the appearance of high-affinity memory antibody responses (36) . Although many aspects of the ICOS and CD28 paralogs are conserved, a number of important differences have emerged. For example, the expression pattern of human and mouse CD28 in thymus and peripheral T cells is considerably different (28, 37, 38) . We have uncovered a difference between ICOS expression in human and mouse CD4 + T cells, where, unlike humans, ICOS is not expressed on recent thymic emigrants in the mouse (23) . ICOS-deficient humans have few TFH cells (39) and impaired T H 1, T H 2, and T H 17 responses (40) , suggesting that ICOS signaling has nonredundant roles for the homeostasis of multiple human CD4 + T cell subsets. Our data suggest that some of these differences between mice and humans could be a result of the earlier expression of ICOS during lymphocyte ontogeny in humans than in mice.
Our data suggest that CD28 and ICOS ligands, in concert with the cytokine milieu, critically dictate the fate of T H 17 cells. Previous studies have shown that CD28 costimulation can provide short-term expansion of T H 17 cells, and our results are consistent with those findings. However, using an ICOS-based culture system, we have identified conditions that permit sustained expansion of human T H 17 cells. Given that ICOSL is constitutively expressed in many tissues, and ICOSL overexpression can result in autoimmunity (41, 42) , our findings raise a ques- . Our data suggest that CD28 may transition T H 17 cells into T H 22 cells, whereas ICOS transitions them into T H 1/T H 17 cells. Additional experiments to understand the potential impact of CD28 signaling on T H 22 cell development will be required. Our data support the idea that the fate of T cell subsets, particularly T H 17 cells, appears more flexible in humans than previously appreciated (5) .
There are several therapeutic implications from these findings. A number of autoimmune and inflammatory conditions are associated with increased T H 17 cells and their associated cytokines. For example, skin lesions in psoriasis show substantial up-regulation of CCL20 and CCR6 (43) . In multiple sclerosis, a subset of patients has disease that is dominated by T H 17 cells, and this biomarker predicts the lack of response to subsequent therapy with IFN-b (44) . The relative balance of APCs with ligands for ICOS and CD28 is likely to play a role in the homeostasis of pathogenic and regulatory T H 17 cell populations. Thus, modulation of ICOS function may have therapeutic utility in certain autoimmune disorders.
T H 17 cells can also promote antitumor immunity in mice and humans (10, 45, 46) . For adoptive therapy, the use of defined cell culture conditions to control CD28 and ICOSL availability may permit the selective growth or depletion of T H 17 cells to abrogate chronic inflammation or enhance antitumor immunity, as demonstrated here. We have shown that ICOS stimulation can be used to generate clinically relevant numbers of human T H 17 lymphocytes with potent antitumor activities. New tumor immunotherapy clinical trials are currently being designed on the basis of the findings reported here that will test the antitumor effects of genetically reprogrammed T H 17 cells.
MATERIALS AND METHODS
Cell purification Blood samples were obtained from the Human Immunology Core of the University of Pennsylvania. Peripheral blood CD4 + T cells were negatively isolated and >95% pure adult subsets of T H 1, T H 2, T H 17, T reg , and TFH CD4 + T cells were further purified as described (18, 26, 27) .
T cell activation with beads or aAPCs
For stimulation, 1 × 10 6 CD4 + T cells were cultured with either 3 × 10 6 activating beads coated with antibodies to CD3, CD28, and/or ICOS or with 0.5 × 10 6 CD32-transduced aAPCs bearing CD80, CD86, CD70, ICOSL, OX40L, or 4-1BBL. The methods of aAPC generation and T cell expansion are described elsewhere (29, 47) . Cultures were monitored for cell volume and enumerated via Coulter Multisizer 3 (Beckman Coulter).
Cell culture and T H 1, T H 2, T H 17, and T reg cell polarization Cells were cultivated in RPMI 1640 culture media as described previously in a 37°C and 5% CO 2 incubator (37). For polarization experiments, cells were seeded with antibody-coated beads or aAPCs. IL-2 (50 to 100 IU/ml) was added at day 3 and media were replaced as described previously (47, 48) . For T H 17 cell polarization, as indicated, IL1b (10 ng/ml), IL-6 (10 ng/ml), IL-23 (20 ng/ml), and neutralizing antibodies (10 mg/ml) against IL-4 and IFN-g (eBioscience) were added at day 0 and maintained throughout the experiment. Experiments were conducted with fetal calf serum containing endogenous sources of TGF-b. In experiments indicated, IL-21 (25 ng/ml) (eBioscience) and an antibody to IL-2 (5 mg/ml) (R&D Systems) were added to T H 17-polarized T cells. For T H 1 cell polarization, IL-12 (5 ng/ml) and neutralizing antibodies against IL-4 (eBioscience) were added at day 0. For T H 2 cell polarization, IL-4 (5 ng/ml) and neutralizing antibodies against IFN-g (eBioscience) were added at day 0 and maintained throughout the experiment. For T reg cell polarization, TGF-b (5 ng/ml) and rapamycin (50 ng/ml) were added at day 0 and maintained throughout the experiment. Cells and supernatant were harvested at various days throughout short-and long-term primary and secondary cultures for intracellular staining and/or ELISA.
Real-time polymerase chain reaction RNA was extracted with the RNAqueous isolation kit (Ambion), and then complementary DNA (cDNA) was transcribed with iScript cDNA Synthesis (Bio-Rad) and used as a template for Taqman polymerase chain reaction (PCR) from the specified samples. Expression of RORC2, Tbx21(T-bet), FoxP3, AHR, c-MAF, IL-17A, IL-21, and IL-23R was assessed with specific primers and probes (Applied Biosystems) via the Applied Biosystems 7500 Fast System. Gene expression was normalized to expression of the human gene b-actin. Relative quantitation was performed with unmanipulated CD4 + T cells as a reference.
Surface and intracellular staining
For intracellular cytokine staining, cells were incubated for 5 hours with PMA (20 ng/ml) (Sigma) and ionomycin (2 mg/ml) (Sigma) and GolgiStop (BD). Surface staining was performed, followed by intracellular staining, as described previously, with an LSR II (BD Biosciences) flow cytometer and FlowJo software (Tree Star Inc.). RORC2, T-bet, and FoxP3 were stained with FoxP3 staining buffers (eBioscience).
Mice
The University of Pennsylvania Institutional Animal Care and Use Committee approved all animal experiments. NSG mice were purchased from The Jackson Laboratory and bred in the vivarium at the University of Pennsylvania. The mice were housed under specific pathogen-free conditions in microisolator cages and given ad libitum access to autoclaved food and acidified water.
In vivo assessment of anti-mesothelin CAR T cells A chimeric anti-mesothelin single-chain variable fragment (scFv) fusion protein containing the 4-1BB and T cell receptor z (TCRz) signaling domains was generated as described previously (35) . M108 xenograft tumors were established as described previously (35) in NSG mice before adoptive transfer of T H 17 cells. Tumors were measured with calipers, and their area was calculated by multiplying the length by the width.
Statistical analysis
Tumor growth data were analyzed by life 
